Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
OKLAHOMA CITY, March 14, 2017 -- Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories; Quality, Reliability and Compatibility, which will be given at the CMO Leadership Awards Ceremony to be held March 22, 2017, at the W Hotel in New York City, NY.
“Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners,” says Louis Garguilo, Executive Editor, Life Science Leader magazine and OutsourcedPharma.com. “Recipients are evaluated by the executives and managers at the sponsors the CMOs have worked, in the 6 critical categories of capabilities, compatibility, expertise, quality, reliability and development. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries.”
“We are honored to be awarded as a leader in the categories of Quality, Reliability and Compatibility by our clients in the CDMO marketplace,” stated Darren Head, President and CEO of Cytovance. “Cytovance Biologics proudly employs a highly experienced team, and we remain ever-cognizant of the significance of providing unparalleled service to our clients. We accept this award as a testament of the dedication and hard work of many within our remarkable company."
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Contact: Cheryl Soerensen [email protected] 405.319.8310
